Mozavaptan
|
| (IUPAC) ime
|
| N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
|
| Klinički podaci
|
| Identifikatori
|
| CAS broj
|
137975-06-5
|
| ATC kod
|
nije dodeljen
|
| PubChem[1][2]
|
119369
|
| ChemSpider[3]
|
106618
|
| Hemijski podaci
|
| Formula
|
C27H29N3O2
|
| Mol. masa
|
427.53 g/mol
|
| SMILES
|
eMolekuli & PubHem
|
| InChI |
|---|
InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)  Y
Key: WRNXUQJJCIZICJ-UHFFFAOYSA-N Y |
|
| Farmakoinformacioni podaci
|
| Trudnoća
|
?
|
| Pravni status
|
℞ Prescription only
|
| Način primene
|
Oralno
|
Mozavaptan (INN) je antagonist vazopresinskog receptora u prodaji od strane kompanije Otsuka. On je odobren u Japanu oktobra 2006. za hiponatremiju (niske nivoe krvnog natrijuma) uzrokovane sindromom neodgovarajućeg izlučivanja antidiuretskog hormona (SIADH) usled tumora koji proizvodi ADH.[4][5]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ H. Spreitzer (November 20, 2006). „Neue Wirkstoffe - Conivaptan” (German). Österreichische Apothekerzeitung (24/2006).
- ↑ „Prous Science: Molecule of the Month November 2006”.
Šablon:Diuretici
Šablon:Neuropeptidni ligandi
